News from the University of Arizona Cancer Center

Our mission is to prevent and to cure cancer.

November 2017
UA Cancer Center Team Identifies a Switch that May Help Target Dormant Cancer Cells

A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant cancer cells, which are resistant to chemotherapy and other treatments. The results were published September in the journal *Cell Reports*.

Cells can enter a sleeplike state known as quiescence, during which they stop growing and dividing. Just as sleep can be deep or shallow, a cell's quiescence also can vary in depth. Altering this depth can make it easier or more difficult for a cell to "wake up" and start dividing again.

Because cancer therapies target cells that are awake and actively dividing, quiescent cancer cells often evade treatment. Metastatic cells, those that have left the primary tumor site and spread to distant organs, are especially good at evading treatment by entering quiescence. After cancer therapy has ended, these cells eventually may wake up and begin dividing again, often very aggressively, leading to cancer recurrence.

The UA Cancer Center's Guang Yao, PhD, UA assistant professor of molecular and cellular biology, is the senior coauthor of the study. His lab investigated ways to use a genetic "dimmer switch" to regulate the dormancy of normal cells and tumor cells. This strategy may be key to targeting metastatic tumors.

According to Dr. Yao, this research could lead to ways to "make quiescence shallower so that those cells cannot be hidden from therapeutic treatment." Dormant cancer cells that are roused from their slumber and begin multiplying would once again be vulnerable to chemotherapies.

Read Full Article

---

UA Cancer Center Team Explores Anti-Breast Cancer Properties of Soy

A University of Arizona Cancer Center research team is engaged in a series of studies to investigate how genistein, a component of soy foods, might suppress the development of breast cancer.

The team’s most recent study, published in *Current Developments in Nutrition*, suggests genistein can protect BRCA1, a gene that plays a pivotal role in thwarting tumor development in breast tissue.
The team is led by **Donato F. Romagnolo, PhD**, professor of nutritional and cancer biology, and **Ornella I. Selmin, PhD**, associate research professor.

---

**UA Cancer Center at the Forefront of Vaginal Microbiome Studies**

The UA Cancer Center's **Melissa M. Herbst-Kralovetz, PhD**, leads the **Women's Health Microbiome Initiative**, an ambitious undertaking that seeks to uncover connections between vaginal microbiota -- the microscopic organisms that reside in the lower reproductive tract -- and women's health. The Initiative, based at the UA College of Medicine - Phoenix, brings together a team of researchers who are investigating how the vagina's microbes interact with the rest of the body to promote or harm women's gynecologic, reproductive and obstetric health.

Dr. Herbst-Kralovetz's lab focuses on the way a dysbiotic vaginal microbiome could promote inflammation, which is a factor in the development of cancer. "The relationship between inflammation and cancer has been clearly established," Dr. Herbst-Kralovetz says. "However, the role of microbiota in promoting inflammation and tumorigenesis, especially in the genital tract, is not well understood."

With so many questions in need of answers, Dr. Herbst-Kralovetz's lab is at the forefront of some of the most exciting research being done at the intersection of the microbiome and women's health. A recent grant from the Mary Kay Foundation is supporting explorations of the link between the vaginal microbiome and endometrial cancer.

---

**NACP Researchers Featured on the Cover of Oncology**

Congratulations to the **Partnership for Native American Cancer Prevention**'s amazing team of researchers, Anna, Dirk, and Jen, whose article, "Initiating Exercise Interventions to Promote Wellness in Cancer Patients and Survivors," made the front cover of *Oncology* last month!

The authors conclude that health-care providers should guide their patients with clear and succinct information about exercise at every visit and emphasize that inactivity should be avoided.
Survivors need to know that exercise is safe and beneficial at all stages of survivorship, with the caveat that exercise should begin slowly and progress gradually to increase volume and intensity of the regimen.

They advocate for a change in our thinking about caring for cancer survivors by encouraging restorative exercise during and following treatment. Exercise at any point in the survivorship trajectory helps to maintain and improve functional ability, body composition, and quality of life.

Melanoma Walk 2017 to Be Held This Saturday, Nov. 4

The UA Skin Cancer Institute at the University of Arizona Cancer Center will present the eighth annual Melanoma Walk on Saturday, Nov. 4, on the UA Mall, 1209 E. University Blvd. Activities begin at 3 p.m. and the walk starts at 4:30 p.m.

Online registration closes on Thursday, November 2, at midnight, but you can still register and walk the day of the event. Remember, we're on Main Campus again this year!

Read Full Article

Dr. Breelyn Wilky Discusses Immune Therapy in Sarcoma for Davenport Family Lecture

On October 23, Breelyn A. Wilky, MD, of the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center delivered a lecture titled "Immunotherapy in Sarcoma: A New Frontier" to an engaged audience in Room 2920.

She sat down with us to chat about her roots in Arizona, her interest in sarcoma, and her hopes for immunotherapy.

Welcome to the University of Arizona!

I’m very excited to be back here -- I grew up in Phoenix. I went to Mountain Point High School near Ahwatukee. I translocated to New Jersey my senior year of high school and I’ve been on the East Coast ever since. Throughout most of high school I was convinced I wanted to be at the University of Arizona -- that’s where I wanted to go to med school. I had the whole plan, and then things
changed. But everything happens for a reason. Had I not moved to New Jersey, there are a million things that would have been different -- people I would have met, choices I would have made.

**What do you miss about Arizona?**
I have to say the Mexican food. You can't find Arizona Mexican food anywhere else. That is near and dear to my heart. There's nothing like it.

**What are you excited to tell us about today in your lecture?**
I am going to be talking about immune therapy for sarcomas -- bone and soft tissue cancers. We'll go through the major treatment paradigms we have in sarcoma today, talk about clinical trials, and where the future is for sarcoma research. I'll spend most of the time speaking about immunotherapy in particular.

Sarcomas are really rare, they're collectively only 1 percent of adult cancer. It's really 100 or more different diseases within the sarcoma umbrella. My major message is how to develop a precision medicine paradigm. Nowadays, we're looking at genetic sequencing to match patients to more targeted therapies. My main research focus is how can we make immunotherapy work for more patients.

**What is your hope for the future of sarcoma treatment?**
My goal would be that one day a patient comes in and, in addition to a pathology report, I want a jump drive where I have the genetic information, the pathology, and hopefully an immune profile. Ideally we'll have tools that we can use to say that this patient's better off being treated with immunotherapy, or this patient is never going to respond. How do we pick out the treatments that are more likely to benefit them? And then use that to inform the next clinical trials.

**I noticed you have a blog. What do you find rewarding about science communication?**
The information out there on the Internet is very hit or miss. Many of my patients are looking for answers on the Internet. It can be challenging to help people sort through what's on the Internet. I wanted to be able to get some major messages across in a controlled fashion. I was doing Facebook, I was doing Twitter, but it wasn't quite right. I decided to start the blog. I try to get these very abstract, complicated concepts that are tough to discuss into some sort of analogy, some sort of layman's terminology, so people can understand what we're doing.
"We only have one competitor -- cancer," said William Cance, MD, Deputy Director of the UA Cancer Center Phoenix. "This event is designed to promote thoughtful discussion and a strategic plan of action to enhance collective projects and discovery."

Phoenix Mayor Greg Stanton delivered opening remarks to the 133 attendees, saying that he, too, believes in the power of collaboration, especially when it's among top cancer research oncologists, academic, clinical and care delivery organizations.

"This important symposium is bringing together the best and brightest minds in your field," Stanton said. "Together, you will pave the way for more scientific discovery."

Read Full Article
Cancer survivors, friends, families and caregivers spent a day learning about healthy living and long-term well-being from cancer experts and patient advocates at "Beyond Cancer: Finding Spirit," a conference focused on survivorship, presented by the UA College of Nursing in partnership with the UA Cancer Center on Sept. 9 at the Westward Look Wyndham Grand Resort and Spa in Tucson.

**Leila Ali-Akbarian, MD, MPH**, medical director of the UA Cancer Center's Supportive Care Clinic, spoke about the "Science of Relaxation," covering brain anatomy, the role of the nervous system in stress and relaxation, and the effects of stress on gene expression and the biochemical changes the body undergoes during relaxation. Dr. Ali explained that chronic stress can cause wear and tear on the body, but improving the ability to recover from stress also can improve the ability to recover from illness.

**Thaddeus "Tad" Pace, PhD**, assistant professor with the UA College of Nursing and biopsychologist with the UA Cancer Center, presented "Overcoming Stress Biology to Promote Wellness in Survivorship." He discussed the connection between the inflammatory response and fatigue in cancer survivors. "Stress has an important place in understanding how we can promote wellness and survivorship," said Dr. Pace. He also spoke about curcumin, a component of turmeric, and researchers' quest to discover if it can benefit people with chemotherapy-related fatigue by putting "the kibosh on the inflammatory process." Though he described himself as a "trained skeptic," he noted that, so far, research into this compound is promising.

[Read Full Article]
SHARED RESOURCE HIGHLIGHT: Behavioral Measurement and Interventions Shared Resource
The Behavioral Measurement and Interventions Shared Resource (BMISR) has more than 25 years of experience providing support to UACC members and other University and national researchers studying human lifestyle behaviors related to cancer prevention and control, including:

- Diet
- Physical activity
- Tobacco exposure
- Quality of life
- Sun safety
- Sexual practices
- Sleep
- Symptom management

BMISR is a unique one-stop resource that provides investigators one access point to several research services ranging from study design consultation to intervention delivery to data analysis.

Examples include:

**Behavioral Research Consulting**
- Advice on selecting or designing questionnaires for behavioral data collection
- Study design/concept development in regard to behavior change theory

**Body Composition**
- Advice on selecting appropriate methodology
- Support for DXA and BIA

**Survey Development, Design, and Data Capture**
- Advice on selecting appropriate platform based on project scope
- Qualtrics and REDCap expertise

**Behavioral Interventions**
- Behavior theory-based interventions
- Motivational interviewing
- Trained bilingual health coaches (diet, physical activity, tobacco cessation, etc.)
- Integrated software for study management and behavioral intervention delivery
- Short Message Service (SMS)

**Training**
- Anthropometry training, including height, weight, waist measurements
- 6-hour introductory course to Motivational Interviewing
- Dietary recall training, including practice call interviews and evaluation on technique
- Standardized interviewing training

The BMISR has ActiGraph Accelerometers/Actigraphy for the collection of physical activity and sleep measures. The BMISR also has the ActiGraph software tools to analyze activity data collected with the devices.

The BMISR has software platforms in place to deliver lifestyle coaching to study participants. Coaches trained in diet, physical activity, and tobacco cessation behavior change are available to support research. In addition, student research assistants are available to assist with conducting screening calls or behavioral assessments by phone. Software platforms can be modified to meet individual study requirements in collaboration with the Arizona Research Laboratory.

We have a wide range of valid and reliable questionnaires for assessing human behaviors. Questionnaire descriptions and samples are located in the BMISR INSTRUMENT REPOSITORY, which is a collection of Arizona questionnaires in addition to proprietary instruments available with permission from other sources.

Read more about the Behavioral Measurement and Interventions Shared Resource here.
Shared Resources to Enhance Research Efforts

The University of Arizona Cancer Center supports eight Shared Resources funded by the Cancer Center Support Grant and two other resources funded by other sources, intended to provide access to technology that enhances the research productivity of the Cancer Center and provides a basis for scientific interaction and consultation, as well as access to services that facilitate the research and strengthen the administrative and organizational cohesion of the center.

The University of Arizona Cancer Center Shared Resources:

- Analytical Chemistry
- Behavioral Measurement and Interventions
- Bioinformatics
- Biostatistics
- Cancer Imaging
- Experimental Mouse
- Flow Cytometry
- Genomics
- Proteomics
- Tissue Acquisition and Cellular/Molecular Analysis

National Conversation

- **New York Times: "Researchers Predict a Quarter-Million New Cases of Breast Cancer in the U.S."**: The American Cancer Society estimates that there will be 252,710 new cases of invasive breast cancer in women in the United States in 2017. Some 40,610 women will die from the disease; mortality is 42 percent higher in black women compared to white women.
- **National Public Radio: "Could Making Cancer Screening Simpler Increase Women's Risk?"**: Could the recent proposal to simplify cervical cancer screening end up missing some cancers -- especially for minority women? The U.S. Preventive Services Task Force relied on seven randomized controlled trials and five observational studies -- mostly from predominantly white countries -- for their decision.
- **The Guardian: "I was meant to be dead by 40 - but I'm still here, living in cancer limbo"**: Perivascular epithelioid cell tumor (PEComa) is a very rare sarcoma subtype. There are no survival statistics, as this requires a minimum of 1,000 patients, and at this time only 114 documented cases of PEComa exist.
- **New York Times: "F.D.A. Approves Second Gene-Altering Treatment for Cancer"**: Yescarta was approved for adults with aggressive forms of non-Hodgkin's lymphoma who have undergone two regimens of chemotherapy that failed. The treatment, considered a form of gene therapy, transforms the
patient's cells into what researchers call a "living drug" that attacks cancer cells.

- **New Scientist: "We may be able to use Zika virus to attack brain cancer cells":** Zika virus targets cells in the brains of fetuses, but could it also be pointed at brain cancer stem cells to treat brain cancer?

---

**Call for Collaborations**

This section is intended to provide a platform for UACC Members to propose collaborative efforts with each other. Any and all ideas are welcome. Contact **Cody Cassidy** with your proposal to be posted here.

---

**Share Your Stories and Ideas**

Please send news items, announcements, calls for collaboration, upcoming events, comments, and anything else that you can think of to **Cody Cassidy**, c.cassidy@uacc.arizona.edu.
NCI Funding Opportunities

If you are interested in pursuing any of these funding opportunities, please contact Cindy Cowen at cowenc@email.arizona.edu.

**Minority Patient-Derived Xenograft (PDX) Development and Trials Center (U54)**
(RFA-CA-17-032)
National Cancer Institute
Application due date: January 18, 2018

**Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)**
(RFA-CA-17-033)
National Cancer Institute
Application due date: January 18, 2018

**Human Tumor Atlases (HTA) Research Centers (U2C)**
(RFA-CA-17-034)
National Cancer Institute
Application due date: January 18, 2018, by 5:00 PM local time of applicant organization.

**Human Tumor Atlases (HTA) Pre-cancer Atlas Research Centers (U2C)**
(RFA-CA-17-035)
National Cancer Institute
Application due date: January 18, 2018, by 5:00 PM local time of applicant organization.

**Human Tumor Atlas Network: Data Coordinating Center (U24)**
(RFA-CA-17-036)
National Cancer Institute
Application due date: January 18, 2018, by 5:00 PM local time of applicant organization.

**Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3)**
(RFA-CA-17-038)
National Cancer Institute
Application due date: January 18, 2018, by 5:00 PM local time of applicant organization.

**Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24)**
(RFA-CA-17-039)
**Research Centers for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (UM1) (RFA-CA-17-042)**
National Cancer Institute
Application due date: January 17, 2018, by 5:00 PM local time of applicant organization.

**Coordinating Center for Improving Management of Symptoms Across Cancer Treatments (IMPACT) (U24) (RFA-CA-17-043)**
National Cancer Institute
Application due date: January 17, 2018, by 5:00 PM local time of applicant organization.

**Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) (RFA-CA-17-044)**
National Cancer Institute
Application due date: January 5, 2018, by 5:00 PM local time of applicant organization.

**Limited Competition: NCI National Clinical Trials Network - Network Group Operations Centers (U10) (RFA-CA-17-056)**
National Cancer Institute
Application due date: January 19, 2018, by 5:00 PM local time of applicant organization.

**Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10) (RFA-CA-17-057)**
National Cancer Institute
Application due date: January 19, 2018, by 5:00 PM local time of applicant organization.

**Limited Competition: NCI National Clinical Trials Network - Canadian Collaborating Clinical Trials Network (U10) (RFA-CA-17-058)**
National Cancer Institute
Application due date: January 19, 2018, by 5:00 PM local time of applicant organization.

**NCI National Clinical Trials Network (NCTN)--Network Lead Academic Participating Sites (UG1) (RFA-CA-17-059)**
National Cancer Institute
Application due date: January 19, 2018, by 5:00 PM local time of applicant organization.

**Limited Competition: NCI National Clinical Trials Network - Network Radiotherapy and Imaging Core Services Center (U24)**
**NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1)**  
(RFA-CA-17-061)  
National Cancer Institute  
Application due date: January 19, 2018, by 5:00 PM local time of applicant organization.

**Building Research Capacity in Global Tobacco Product Regulation Program (U18)**  
(RFA-FD-18-003)  
Food and Drug Administration  
Application due date: December 18, 2017 by 11:59 PM Eastern Time.

**Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)**  
(PAR-18-324)  
National Cancer Institute  
Application Receipt/Submission Date(s): New applications: February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020; October 5, 2020, by 5:00 PM local time of applicant organization.

**Simulation Modeling and Systems Science to Address Health Disparities (R01-Clinical Trial Not Allowed)**  
(PAR-18-331)  
National Cancer Institute  
Application Receipt/Submission Date(s): January 10 2018; June 6, 2018; January 8, 2019; June 7, 2019 , by 5:00 PM local time of applicant organization.

Minority-Patient Derived Xenograft (PDX) Development and Trial Center (PDTC) Network (U54)  
(RFA-CA-17-032)  
National Cancer Institute  
Application due date: January 18, 2018, by 5:00 PM local time of applicant organization.

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)  
(RFA-CA-17-033)  
National Cancer Institute  
Application due date: January 18, 2018, by 5:00 PM local time of applicant organization.

Immuno-Oncology Translational Network (IOTN): Cancer Immunotherapy Research Projects (U01)  
(RFA-CA-17-045)  
National Cancer Institute  
Application due date: January 16, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01)  
(RFA-CA-17-046)  
National Cancer Institute  
Application due date: January 16, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (DMRC) (U24)  
(RFA-CA-17-047)  
National Cancer Institute  
Application due date: January 16, 2018, by 5:00 PM local time of applicant organization.

Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24)  
(RFA-CA-17-048)  
National Cancer Institute  
Application due date: January 16, 2018, by 5:00 PM local time of applicant organization.

Innovation Corps (I-Corps) at NIH Program for NIH and CDC Translational Research (Admin Supp)  
(PA-18-314)  
National Cancer Institute  
Application due date: December 18, 2017, by 5:00 PM local time of applicant organization.

Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)  
(PAR-17-306)  
National Cancer Institute  
Application due date: New applications: February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020; October 5, 2020, by 5:00 PM local time of applicant organization. Resubmission applications: March 5, 2018; November 5, 2018; July 5, 2019; March 5, 2020; November 5, 2020, by 5:00 PM local time of applicant organization.

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 - Clinical Trials Not Allowed)  
(PAR-18-310)  
National Cancer Institute  
Application due date: February 14, 2018; July 10, 2018; October 8, 2018; February 13, 2019; July 10, 2019; October 8, 2019; February 13, 2020; July 10, 2020; October 8, 2020, by 5:00 PM local time of applicant organization.

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for years 2018, 2019 and 2020 (P50)  
(PAR-18-313)  
National Cancer Institute  
National Institute of Dental and Craniofacial Research  
Application due date: January 25, 2018; May 25, 2018; September 25, 2018, by 5:00 PM local time of applicant organization.
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 - Clinical Trials Not Allowed) *(PAR-18-317)*
National Cancer Institute
Application due date: February 14, 2018; July 10, 2018; October 8, 2018; February 13, 2019; July 10, 2019; October 8, 2019; February 13, 2020; July 10, 2020; October 8, 2020, by 5:00 PM local time of applicant organization.

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed) *(PAR-18-303)*
National Cancer Institute
Application due date: January 5, 2018; April 5, 2018, by 5:00 PM local time of applicant organization.

NCI Outstanding Investigator Award (R35) *(PAR-17-494)*
National Cancer Institute
Application due date: November 28, 2017, by 5:00 PM local time of applicant organization.

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) *(PAR-17-496)*
National Cancer Institute
Application due date(s): May 14, 2018; May 14, 2019; May 14, 2020, by 5:00 PM local time of applicant organization.

Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional) *(PA-17-495)*
National Cancer Institute
Application due date: Standard dates apply

Lymphatics in Health and Disease in the Digestive System (R01 - Clinical Trials Not Allowed) *(RFA-DK-17-016)*
National Institute of Diabetes and Digestive and Kidney Diseases
Application due date: February 2, 2018, by 5:00 PM local time of applicant organization.

Pediatric Immunotherapy Translational Science Network (PI-TSN)(U01) *(RFA-CA-17-051)*
National Cancer Institute
Application due date: December 19, 2017 by 5:00 PM local time of applicant organization

Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01) *(RFA-CA-17-052)*
National Cancer Institute
Application due date: January 17, 2018, by 5:00 PM local time of applicant organization.
Research to Improve Native American Health (R21 Clinical Trial Optional) (PAR-17-464)
National Cancer Institute
Application due date: May 14, 2018; May 14, 2019; May 14, 2020, by 5:00 PM local time of applicant

Collaborative Program Grant for Multidisciplinary Teams (RM1) (PAR-17-340)
Application due date: January 25, 2018; May 25, 2018; January 25, 2019; May 25, 2019; January 25, 2020; May 25, 2020, by 5:00 PM local time of applicant organization.

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed) (PAR-17-475)
Application due date: November 27, 2017 by 5:00 PM local time of applicant organization

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed) (PAR-17-476)
Application due date: November 27, 2017 by 5:00 PM local time of applicant organization

Application due date: November 27, 2017 by 5:00 PM local time of applicant organization

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01) (PAR-17-473)
Application due date: November 27, 2017 by 5:00 PM local time of applicant organization

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) (RFA-CA-17-041)
Application due date: January 9, 2018 by 5:00 PM local time of applicant organization

Notice of Correction to Activity Code in PA-17-460 "Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed) (NOT-CA-17-078)
Application due date: January 16, 2018

Notice of NCI's participation on PA-17-461 "Symptoms Cluster Characterization in Chronic Conditions (R21) (NOT-CA-17-082)
Application due date: January 16, 2018

Notice of NCI's participation on PA-17-462 "Symptoms Cluster Characterization in Chronic Conditions (R01) (NOT-CA-17-083)
Application due date: January 5, 2018
Consortium on Translational Research in Early Detection of Liver Cancer (Clinical and Research Centers (U01))
(RFA-CA-17-025)
Application due date: October 24, 2017 by 5:00 PM local time of applicant organization

Coordinating Center for the Consortium of Translational Research in Early Detection of Liver Cancer (U24)
(RFA-CA-17-028)
Application due date: October 24, 2017 by 5:00 PM local time of applicant organization

Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01)
(PAR-17-458)
Application due date: January 31, 2018, July 31, 2018, January 31, 2019, July 31, 2019

Symptom Cluster Characterization in Chronic Conditions (R01)
(PA-17-462)
Application due date: February 5, 2018; June 5, 2018; October 5, 2018

Symptom Cluster Characterization in Chronic Conditions (R21)
(PA-17-461)
Application due date: February 16, 2018; June 16, 2018; October 16, 2018

Biology of Lung, and Head and Neck Preneoplasias (R21)
(PA-17-460)
Application due date: February 16, 2018; June 16, 2018; October 16, 2018

Biology of Lung, and Head and Neck Preneoplasias (R01)
(PA-17-459)
Application due date: February 5, 2018; June 5, 2018; October 5, 2018

Metabolomics Core for the Undiagnosed Diseases Network (UDN) Phase II (U01)
(RFA-RM-17-015)
Application due date: November 2, 2017

Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)
(RFA-CA-17-031)
Application due date: October 26, 2017

Limited Competition: Lasker Clinical Research Scholars Transition Award (R00)
(PAR-17-450)
Application due date: January 7, 2018; January 25, 2018; May 7, 2018; May 25, 2018; September 7, 2018

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01)
(RFA-CA-17-029)
Application due date: October 24, 2017; January 23, 2018
Collaborative Research Network for Fusion Oncoproteins in Childhood Cancers (U54) (RFA-CA-17-049)
Application due date: November 15, 2017

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01) (PA-17-440)
Application due date: February 5, 2018; June 5, 2018

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21) (PA-17-449)
Application due date: February 16, 2018; June 16, 2018

Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21) (PA-17-446)
Application due date: February 16, 2018; June 16, 2018

NIBIB Exploratory/Developmental Research Grant Program (R21) (PAR-17-441)
Application due date: February 16, 2018; June 16, 2018

Assay development and screening for discovery of chemical probes or therapeutic agents (R01) (PAR-17-438)
Application due date: February 5, 2018; June 5, 2018

Synthetic Biology for Engineering Applications (R01) (PAR-17-334)
Application due date: February 5, 2018; June 5, 2018

Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01) (PA-17-330)
Application due date: February 5, 2018; June 5, 2018

Tobacco Regulatory Science (R01) (RFA-OD-17-013)
Application due date: February 13, 2018, July 17, 2018, February 13, 2019

Tobacco Regulatory Science (R21) (RFA-OD-17-014)
Application due date: February 13, 2018, July 17, 2018, February 13, 2019

Tobacco Regulatory Science Small Grant Program for New Investigators (R03) (RFA-OD-17-012)
Application due date: February 13, 2018, July 17, 2018, February 13, 2019

Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21) (PA-17-323)
Application due date: March 16, 2018; July 16, 2018; November 16, 2018

**Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03)** *(PA-17-324)*
Application due date: March 16, 2018; July 16, 2018; November 16, 2018

**Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)** *(PA-17-325)*
Application due date: February 5, 2018; June 8, 2018; October 5, 2018

**Administrative Supplements for Research on Dietary Supplements (Admin Supp)** *(PA-17-307)*
Application due date: January 15, 2018; or April 15, 2018

**PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])** *(PA-17-302)*
Application due date: January 5, 2018, April 5, 2018

**PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])** *(PA-17-303)*
Application due date: January 5, 2018, April 5, 2018

**U.S. Tobacco Control Policies to Reduce Health Disparities (R01)** *(PAR-17-217)*
Application due date: June 13, 2018; October 11, 2018; June 13, 2019; October 11, 2019; June 15, 2020

**U.S. Tobacco Control Policies to Reduce Health Disparities (R21)** *(PAR-17-218)*
Application due date: June 13, 2018; October 11, 2018; June 13, 2019; October 11, 2019; June 15, 2020

**Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21)** *(PA-17-288)*
Application due date: February 16, 2018; June 16, 2018

**Leveraging Population-based Cancer Registry Data to Study Health Disparities (R01)** *(PA-17-289)*
National Cancer Institute
Application due date: February 5, 2018

**Tobacco Regulatory Science (R21)** *(RFA-OD-17-009)*
Application due dates: February 13, 2018, July 17, 2018; February 13, 2019

**Tobacco Regulatory Science Small Grant Program for New Investigators (R03)** *(RFA-OD-17-008)*
Application due dates: February 13, 2018, July 17, 2018; February 13, 2019

**Tobacco Regulatory Science (R01)**
(RFA-OD-17-007)
Application due dates: February 13, 2018, July 17, 2018; February 13, 2019

**(U24) Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine**
(PAR-16-385)
Application due date(s): November 17, 2017; June 14, 2018

If you are interested in pursuing any of these funding opportunities, please contact Cindy Cowen at cowenc@email.arizona.edu.

---

Visit the UACC Website

University of Arizona Cancer Center
1515 N. Campbell Ave.
Tucson, AZ 85724

STAY CONNECTED:

The University of Arizona Cancer Center, PO Box 245024, Tucson, AZ 85724-5013

SafeUnsubscribe™ mogollon@email.arizona.edu
Forward this email | Update Profile | About our service provider
Sent by ccassidy@uacc.arizona.edu in collaboration with

Try it free today